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ABSTRACT
Objective Altered microbiota composition, changes in
immune responses and impaired intestinal barrier functions
are observed in IBD. Most of these features are controlled
by proteases and their inhibitors to maintain gut
homeostasis. Unrestrained or excessive proteolysis can lead
to pathological gastrointestinal conditions. The aim was to
validate the identified protease IBD candidates from a
previously performed systematic review through a genetic
association study and functional follow-up.
Design We performed a genetic association study in a
large multicentre cohort of patients with Crohn’s disease
(CD) and UC from five European IBD referral centres in a
total of 2320 CD patients, 2112 UC patients and 1796
healthy controls. Subsequently, we did an extensive
functional assessment of the candidate genes to explore
their causality in IBD pathogenesis.
Results Ten single nucleotide polymorphisms (SNPs) in
four genes were significantly associated with CD: CYLD,
USP40, APEH and USP3. CYLD was the most significant
gene with the intronically located rs12324931 the
strongest associated SNP (pFDR=1.74e-17, OR=2.24 (1.83
to 2.74)). Five SNPs in four genes were significantly
associated with UC: USP40, APEH, DAG1 and USP3.
CYLD, as well as some of the other associated genes, is
part of the ubiquitin proteasome system (UPS). We
therefore determined if the IBD-associated adherent-
invasive Escherichia coli (AIEC) can modulate the UPS
functioning. Infection of intestinal epithelial cells with the
AIEC LF82 reference strain modulated the UPS turnover by
reducing poly-ubiquitin conjugate accumulation, increasing
26S proteasome activities and decreasing protein levels of
the NF-κB regulator CYLD. This resulted in IκB-α
degradation and NF-κB activation. This activity was very
important for the pathogenicity of AIEC since decreased
CYLD resulted in increased ability of AIEC LF82 to replicate
intracellularly.
Conclusions Our results reveal the UPS, and CYLD
specifically, as an important contributor to IBD
pathogenesis, which is favoured by both genetic and
microbial factors.
INTRODUCTION
Crohn’s disease (CD) and ulcerative colitis (UC) rep-
resent two distinct forms of chronic inflammation of
the gastrointestinal tract, collectively called IBD.
Although the categories of underlying pathogenic
factors (genetic, environmental, microbial and
immunological factors) are roughly the same, they
are evidently clinicopathologically distinct with dif-
ferences in disease location, behaviour and severity;1
and with different pathogenic mechanisms, which
to date are not entirely clear. Genome-wide associ-
ation studies (GWAS) and meta-analyses have identi-
fied 99 susceptibility loci.2–4 More recently a
meta-analysis of CD and UC GWAS, with extensive
validation of significant findings and a combined
total of more than 75 000 cases and controls
brought the total number to 163 IBD loci: 110 for
both CD and UC, 30 CD-specific and 23
UC-specific.5 Still, these loci explain only 15%–
23% of the heritability to these diseases, and for
Significance of this study
What is already known on this subject?
▸ Alterations in the composition and diversity of
the gut microbiota play a key role in the
establishment and maintenance of IBD.
▸ Increased numbers of mucosa-associated
adherent-invasive Escherichia coli (AIEC) are
observed in patients with Crohn’s disease (CD).
▸ Proteases and protease inhibitors tightly
regulate microbiota composition, immune
response and intestinal barrier function to
maintain gut homeostasis.
▸ Pivotal to the host inflammatory responses to
commensal and pathogenic bacteria is the
NF-κB pathway which is largely regulated by
the ubiquitin proteasome system (UPS). The
main function of the UPS is the degradation of
unneeded or damaged proteins.
▸ CYLD is a de-ubiquitinase and is part of the
UPS. It mainly acts as a negative regulator of
NF-κB to protect the host from an over-reactive
inflammatory response.
▸ The expression of CYLD is significantly
downregulated in the intestine of CD patients.
Cleynen I, et al. Gut 2014;63:1265–1274. doi:10.1136/gutjnl-2012-303205 1265
Inflammatory bowel disease
 group.bmj.com on July 10, 2014 - Published by gut.bmj.comDownloaded from 
many of the loci the exact causal gene(s) have not yet been
identified.
Alterations in the composition and diversity of the gut micro-
biota have shown to play a key role in IBD aetiology.6 Also, in
patients with CD and UC, high concentrations of bacteria forming
a biofilm on the surface of the gut mucosa,7 and increased
numbers of mucosa-associated Escherichia coli are observed.8 9
These bacteria, called adherent-invasive Escherichia coli (AIEC),
colonise the ileal mucosa of CD patients.10 They are able to
adhere to and invade intestinal epithelial cells, and to survive and
highly replicate within macrophages leading to the secretion of
large amounts of TNF-α.11 12 Gut colonisation triggered by adhe-
sion and invasion of AIEC is accompanied by a breakdown of the
mucosal barrier, sustaining the inflammatory response.13
Besides altered microbiota composition, changes in immune
responses and impaired intestinal barrier functions are observed
in IBD.14 Each of these features is controlled by proteases and
protease inhibitors in order to maintain gut homeostasis.
Unrestrained or excessive proteolysis can lead to pathological
gastrointestinal conditions: increased proteolytic activity has
been found in the secretions of colonic biopsy samples from
patients with IBD.15 Exactly which proteases and inhibitors are
involved in the context of IBD is currently unknown. In a previ-
ously performed and published systematic review of protease
(inhibitor) genes in IBD, we ranked the known protease (inhibi-
tor) genes according to the amount of evidence present in litera-
ture for linkage and/or association of their genomic location
with IBD.16 In the present study, we are following up on the
identified candidates from that systematic review through a
genetic association study in CD and in UC on the common var-
iants in the top-ranked genes and functional analyses on the
most promising candidate genes to explore their candidacy as




A genetic association study was performed in two stages. First,
182 tagging SNPs in 23 protease (inhibitor) genes (table 1) were
genotyped in an exploratory cohort (University Hospital Leuven,
Belgium) of 650 CD and 721 UC patients, and 542 healthy con-
trols (HC) using Sequenom. The candidate genes were selected
based on the results from the previously published systematic
review.16 Nominally significant SNPs (puncorrected<0.05) were then
validated in an independent cohort constituting a total of 1670
CD patients, 1391 UC patients and 1254 HC from four European
countries: the Netherlands (ICC/Dutch), Hungary, the UK
(Exeter) and Switzerland (table 2) using KASPar chemistry
(KBioscience). An FDR corrected p (pFDR)<0.05 was considered
statistically significant.
Detailed information on the study samples, SNP selection and
statistical analysis for the genetic association study is provided in
online supplementary materials and methods. Overall patient
characteristics are given in table S1.
Functional studies with AIEC reference strain LF82
Cell culture
The intestinal epithelial cell line T84 (ATCC, CCL-248) was
maintained in an atmosphere containing 5% CO2 at 37°C in the
culture medium recommended by ATCC.
Bacterial strain and culture
E coli strain LF82, isolated from a chronic ileal lesion of a CD
patient, was used as the AIEC reference strain.8 Isogenic mutants
Significance of this study
What are the new findings?
▸ Polymorphisms in CYLD, USP40, APEH and USP3 genes are
significantly associated with CD. The strongest association
was with CYLD, a de-ubiquitinating enzyme and key
regulator of the NF-κB pathway, located adjacent to the
well-established CD susceptibility gene NOD2.
▸ Polymorphisms in USP40 and USP3 genes, and several SNPs
located at 3p21 (USP4/DAG1/APEH/MST1) are significantly
associated with UC.
▸ We show that AIEC bacteria modulate the UPS turnover by
reducing the accumulation of poly-ubiquitin conjugates,
increasing 26S proteasome activities and decreasing the
protein level of the NF-κB regulator CYLD, in turn leading to
IκB-α degradation and subsequent NF-κB activation.
▸ The effect of AIEC bacteria on CYLD protein levels is very
important for the pathogenicity of AIEC bacteria since
decreased CYLD resulted in an increased ability of AIEC LF82
to replicate intracellularly.
How might it impact on clinical practice in the
foreseeable future?
▸ Our results indicate that proteasome inhibitor therapy
targeting the UPS could be efficient in IBD. A specific
example for future use in IBD could be bortezomib, which
was the first therapeutic proteasome inhibitor tested in
humans and which is successfully used in cancer treatment.
Table 1 Overview selected candidate genes for the genetic
association study
Gene Chr Position (bp)*
USP40 2q37 234 384 166–234 475 428
USP19 3p21 49 145 479–49 158 371
USP4 3p21 49 315 264–49 378 145
DAG1 3p21 49 506 146–49 573 048
APEH 3p21 49 711 435–49 721 396
MST1 3p21 49 721 380–49 726 934
PSMB8 6p21 32 808 494–32 812 480
PSMB9 6p21 32 811 913–32 847 364
MEP1A 6p12 46 761 127–46 807 515
MMP3 11q22 102 706 532–102 714 534
USP15 12q14 62 654 119–62 811 211
USP3 15q22 63 796 793–63 886 839
POL3S 16p11 31 093 907–31 100 949
PRSS8 16p11 31 142 756–31 147 083
PRSS36 16p11 31 150 246–31 161 415
LONP2 16q12 48 278 207–48 395 747
CYLD 16q12 50 775 961–50 835 846
MMP2 16q12 55 512 742–55 540 603
MMP15 16q21 58 059 470–58 080 805
MEP1B 18q12 29 769 987–29 800 364
ELA2 19p13 852 291–856 242
C3 19p13 6 677 846–6 730 573
QPCTL 19q13 46 195 741–46 207 240
*Coordinates in NCBI GRCh37.
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of LF82 deleted for the FimH, lpfA, FliC, OmpA, OmpC, OmpF
and the lpfA genes17–21 were also used in this study.
siRNA tr3ansfection
The siRNA oligonucleotides CYLD-si2 (CGCTGTAA
CTCTTTAGCAT) were used in this study.22 For control siRNA
treatment, siRNAs targeting luciferase (TTCUCCGAAC
GTGTCACGT) were used. Cells were transfected with siRNAs
using Oligofectamine (Invitrogen) according to the manufacturer’’s
protocol.
Plasmids and transfection
T84 cells were used to amplify CYLD by PCR with the platinum
Taq DNA polymerase (Invitrogen) according to the manufac-
turer’s instructions. The PCR reaction was performed with the
primers, CYLDF1 (50-GACAGCATGGACACCACGTT-30) and
CYLDR1 (50-TTGCCTTTCCCGATGACCC-30), designed on
the full sequence of CYLD (transcript ID=ENST00000569418)
and with the following temperature cycle: 94°C for 2 min fol-
lowed by 40 cycles of 94°C for 30 s, annealing at 50°C for 30 s,
and 72°C for 3 min. A final extension incubation of 72°C for
5 min was followed by 5 min at 5°C. The PCR product was
purified with the Nucleospin extract II kit (Macherey-Nagel)
and cloned into pCR2.1 vector with the TA Cloning Kit
(Invitrogen) according to the manufacturer’s instructions. The
resulting plasmid was digested with HindIII and XbaI, and the
excised fragment was ligated into pEGFP-C1 cut with the same
enzymes. T84 cells were transfected with plasmids pEGFP-C1
or pEGFP-C1-CYLD (100nM) and Lipofectamine 2000
(Invitrogen) according to the manufacturer’s protocol.
Invasion and intracellular survival assays
For adhesion assays, monolayers were infected for 3 h at a
multiplicity of infection (MOI) of 10 bacteria per cell. Bacterial
invasion of T84 cells was performed using the gentamycin pro-
tection assay.11 At 1 and 24 h postinfection, the number of
intracellular bacteria was determined by counting the number of
colony-forming units. To determine the effect of MG132 on
bacterial adhesive and invasive abilities, T84 cells were infected
for 3 h at an MOI of 10 in the presence of MG132 (25 mM) or
vehicle (dimethyl solfoxide, DMSO, 0.2%). For bacterial inva-
sion assay, T84 cells were washed five times in phosphate buffer
saline (PBS) after 3 h infection in presence of MG132 or
vehicle. The number of intracellular bacteria was determined by
counting the number of colony-forming units without adding
MG132 or vehicle during the postinfection period. One
representative dataset of at least three independent experiments
was presented where appropriate.
Chymotrypsin-like activities of 26S proteasome
Monolayers were infected for 3 h at an MOI of 100 or 200 bac-
teria per cell and washed twice with ice-cold PBS and then
scraped in ice-cold HEPES buffered saline (150 mmol/L NaCl,
5 mmol/L KCl and 10 mmol/L HEPES, pH 7.4).22 Cells were
pelleted (14 000 g for 20 s at room temperature) and then resus-
pended in ice-cold lysis buffer (10 mmol/L Tris (pH 7.4),
5 mmol/L MgCl2 and 50 U/mL deoxyribonuclease and ribo-
nuclease, plus complete protease inhibitor cocktail; Roche
Molecular Biochemicals). Protein concentrations were deter-
mined by Bradford assay, and samples stored at −80°C until use.
Chymotrypsin-like activity of the proteasome was determined
by measuring the hydrolysis of the fluorogenic substrates
succinyl-Leu-Leu-Val-Tyr-7-amido-4-methylcoumarin (AMC)
(Sigma). To measure peptidase activity, 15 mL of lysate contain-
ing 20 μg protein was added to 60 μL medium containing
50 mM Tris (pH 7.5), 10 mM MgCl2, 1 mM dithiothreitol and
300 μM succinyl-Leu-Leu-Val-Tyr-7-AMC. The peptidase activity
was determined by measuring the accumulation of the fluoro-
genic cleavage product (AMC) using the FLX800 fluorimeter
(Bio-Tek) with 380 and 440 nm excitation and emission wave-
lengths, respectively. The difference between arbitrary fluores-
cence units recorded with or without 40 or 100 μmol/L of the
proteasome inhibitor MG132 (Affiniti) in the reaction medium
was calculated, and the final data were corrected by the amount
of protein in the reaction. The time course for the accumulation
of AMC after hydrolysis of the substrate was analysed by linear
regression to calculate peptidase activities, that is, the slopes of
best fit of accumulated AMC versus time. Values were expressed
in relative fluorescence unit per microgram of protein per
minute. One representative dataset of at least three independent
experiments was presented where appropriate. At each experi-
ment, monolayers treated with MG132 (25 mM) or vehicle
(DMSO, 0.2%) were treated like the uninfected or infected
cells.
Western blotting
Monolayers were infected for 3 h at an MOI of 100 in presence
or not of MG132 (25 mM) or vehicle (DMSO, 0.02%) and
washed twice with ice-cold PBS and then scraped in NP40 lysis
buffer (50 mmol/L Tris HCl, 150 mmol/L NaCl, 40 mmol/L
EDTA, 1% NP40, pH 7.5 plus complete protease inhibitor
cocktail; Roche Molecular Biochemicals) containing 5 mmol/L
N-ethyl-maleimide to protect Ub protein conjugates. Whole cell
extracts were subjected to SDS-PAGE on 12% or 7.5% (wt/vol)
acrylamide gels. Protein concentrations were determined by
Bradford assay. Western immunoblotting was performed accord-
ing to the procedure of Towbin.23 Proteins were electroblotted
onto nitrocellulose membranes (Amersham International). The
membranes were immunoblotted for CYLD (rabbit anti-CYLD,
1:1000, Thermo scientific), IkB-a (Rabbit anti- IkB-a, 1:200,
Santa Cruz Biotechnology Inc), β-actin (rabbit anti-β-actin, Santa
Cruz Biotechnology Inc.) and for polyUb chains (anti-FK1,
1:1000, Affiniti) Immunoreactants were detected using horse-
radish peroxidase-conjugated antirabbit or antimouse immuno-
globulin G antibody, ECL reagents (Amersham Biosciences) and
autoradiography. Image J software was used to estimate protein
quantity. Results are expressed as protein amount relative to
β-actin, or normalised against the amount of proteins (deter-
mined following Ponceau Red staining) for poly-ubiquitinated
proteins.
Table 2 Number of individuals per dataset
CD UC Healthy controls
Exploratory cohort
Leuven 650 721 542
Validation cohorts
The Netherlands 634 528 900
Hungary 377 290 354
The UK 432 432 0
Switzerland 227 141 0
Subtotal validation cohort 1670 1391 1254
Total 2320 2112 1796
CD, Crohn’s disease.
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Confocal microscopy for NF-κB and poly-ubiquitin conjugates
localisation
T84 cells were plated at a concentration of 2.105 per cm2 in 24
well plates containing sterile cover slips and grown at 37°C for
48 h. Cells were infected at an MOI of 100 in presence or not
of MG132 (25 mM) or vehicle (DMSO, 0.2%). After infection,
the cells were washed four times with PBS prewarmed to 37°C
and fixed onto the cover slips by incubation in 3.7% formalde-
hyde for 15 min. Cells were then washed with PBS and permea-
bilised by incubation in 0.1% Triton for 15 min at room
temperature. The cover slips were blocked in blocking buffer
(5% decomplemented serum, 3% bovine serum albumin (BSA),
0.025% triton) during 2 h at room temperature. Antibody to
the NF-κB p65 subunit or FK1 (1:500) was added in blocking
buffer and incubated for 2 h at room temperature. The cover
slips were washed six times with PBS and incubated with
Hoechst solution (final concentration of 0.5 μg/mL, Sigma) and
CY3 antibody (1:300) during 1 h in the dark. Cover slips were
then washed six times each with PBS and mounted onto slides
using Fluorescent mounting medium (mowiol). The nuclear
translocation of p65 was imaged using a Zeiss LSM 510 META
confocal microscope equipped with a Zeiss 37°C incubation
system. Images were analysed using the Zeiss LSM Image
Examiner.
Statistical analysis
Data were analysed by Student’ t test. A p≤0.05 was considered
statistically significant. Data are expressed as the means±SEM.
RESULTS
Genetic association study of protease (inhibitor) genes
Of the 182 tagging SNPs in 23 candidate genes, 26 SNPs were
nominally significant in the exploratory cohort. With one SNP
deleted from further analysis because it failed quality control
(QC), we finally had 25 SNPs with genotyping results in both
the exploration and validation cohorts. Association results of
these 25 SNPs in the combined cohort (2320 CD, 2112 UC and
1796 HC) are listed in table 3. Ten SNPs were significantly asso-
ciated (pFDR<0.05) with CD. They were located in CYLD
(16q12), USP40 (2q37), APEH (3p21) and USP3 (15q22). Five
SNPs were significantly associated with UC, being located in
USP40 (2q37), DAG1 and APEH (both on 3p21), and USP3
(15q22).
In CD, the most significant finding was for rs12324931 with
a combined p value of 1.74e-17 (OR=2.24 (1.83 to 2.74)).
Rs12324931 is located intronically in the CYLD gene. Three
other SNPs in CYLD (2 intronic, and 1 upstream)—all in low
linkage disequilibrium (LD) with rs12324931 (r2<0.1) but with
moderate LD between them (0.5<r2<0.7)—were also asso-
ciated with CD: rs17314544 (pFDR=1.42e-08, OR=0.76 (0.66
to 0.88)), rs2302759 (pFDR=4.86e-02, OR=0.88 (0.76 to
1.01)) and rs7205423 (pFDR=1.60e-07, OR=1.23 (1.05 to
1.43)). Haplotype analysis showed a significant association of
this 3-SNP block with CD (pomnibus=2.69e-14). For none of the
associated CYLD SNPs, a clear function is eminent. They are
non-coding and are not identified as being expression quantita-
tive trait loci (eQTLs) (table 3) or transcription factor binding
sites. CYLD is located on chromosome 16q12, 9 kb downstream
of the well-established CD susceptibility gene NOD2. We there-
fore tested whether the observed signals in CYLD were acting
independently or were driven by the three major NOD2
CD-risk variants. Genotypes were obtained for rs2066844
(p.R702W), rs2066845 (p.G908R) and rs2066847
(p.L1007fsinsC). Overall, relatively low LD was observed
between the NOD2 and CYLD SNPs with an average r2=0.10,
but there is a high correlation between rs2066844 and
rs12324931: r2=0.83. Conditional on rs2066844, rs2066845
and rs2066847, a significant independent association was
shown for rs12324931: p=5.76e-5, p=2.03e-17 and
p=4.36e-18, respectively. When including all three NOD2
mutations in a single conditional logistic regression test,
rs12324931 was still significantly associated (p=2.92e-05).
Also, when stratifying based on NOD2 carrier status,
NOD2-negative patients (not carrying any of the three NOD2
risk alleles) showed a significant association with rs12324931
(p=0.001, OR=4.05 (1.68 to 9.73)). None of the CYLD SNPs
were associated with UC.
A detailed analysis of the other associated SNPs is provided in
table 3 and online supplementary results (also see figure S1 and
tables S2-S4). Inherent to the way the candidate protease
(inhibitor) genes studied here were selected, we found that also
the other associated proteases in this study are located near
known susceptibility genes: ATG16L1 for USP40 and MST1 for
the genes located at 3p21 (USP4, APEH, DAG1). Although the
results of the genetic studies cannot prove that these genes are
definitely causal, we could show that there are probably multiple
variants in these loci (allelic heterogeneity) that are important in
IBD pathogenesis (see online supplementary results).
Importance of the role of CYLD in CD as revealed by
CD-associated bacteria
The genetic results point towards the implication of CYLD in
IBD pathogenesis. We therefore next assessed if this gene indeed
could be functionally involved. It has been reported that some
bacteria and viruses are able to modulate CYLD.23–25 We there-
fore first investigated if mucosa-associated bacteria known to
abnormally colonise the gastrointestinal tract of IBD patients
would also be able to modulate CYLD. As AIEC are the proto-
type bacteria recognised worldwide as abnormally colonising
the gut of IBD patients, we tested the effect of the AIEC refer-
ence strain LF82 on CYLD in T84 intestinal epithelial cells. In
AIEC LF82 infected T84 cells, 40% decreased CYLD protein
levels were observed (p<0.00001) (figure 1A). CYLD is shown
to be significantly downregulated in the intestine of CD
patients.26 As CYLD could also act as a negative regulator for
immune and inflammatory response against invading bac-
teria,27 28 we tested if a decrease in CYLD expression affects the
ability of AIEC LF82 to invade and replicate intracellularly.
Transfection of T84 cells with CYLD siRNA (figure 1B) resulted
in a significant increase in the ability of AIEC LF82 to invade
(p<0.0001) and replicate intracellularly (p<0.01), compared
with cells transfected with scramble siRNA (taken as 100%),
with values reaching 151% and 223% (figure 1C,D). In con-
trast, we observed that overexpression of CYLD in T84 cells
transfected with cloned CYLD cDNA into PEGFP-C1 vector did
not modify the level of internalised bacteria as shown at 1 h
postinfection but significantly decreased by 22.7% the number
of intracellular bacteria at 24 h postinfection (p=0.005 vs T84
cells transfected with the empty vector) (figure 1E–G).
Altogether, these results indicated that a decrease in CYLD
protein level can favour the invasion and the intracellular repli-
cation of AIEC bacteria.
Importance of the role of the UPS in CD
CYLD, as well as many of the other genes where we found evi-
dence for association with IBD (USP40, USP3, USP4, APEH), is
part of the ubiquitin proteasome system (UPS). Its main function
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Table 3 Significant associations with CD and UC in the combined cohort
CD UC



















rs838548 2 234092357 USP40 Intron G 0.20 0.24 1.01E-03 1.29 (1.12 to 1.47) 1.06 (0.77 to 1.46) 0.20 8.26E-01 1.06 (0.92 to 1.22) 0.9 (0.64 to 1.27)
rs4047198 2 234119639 USP40 Intron G 0.20 0.23 9.97E-04 1.30 (1.13 to 1.49) 0.98 (0.71 to 1.36) 0.20 8.03E-01 1.07 (0.93 to 1.23) 0.88 (0.63 to 1.24)
rs12472244 2 234131582 USP40 Intron G 0.23 0.19 1.23E-03 0.79 (0.69 to 0.91) 0.91 (0.66 to 1.24) 0.20 4.45E-02 0.78 (0.68 to 0.89) 1.22 (0.9 to 1.65)
rs13078949 3 49336795 USP4 30 WDR6* G 0.42 0.41 3.09E-01 0.92 (0.80 to 1.05) 0.98 (0.83 to 1.17) 0.41 4.75E-01 0.91 (0.79 to 1.05) 1.01 (0.84 to 1.20)
rs885592 3 49472887 DAG1 Intron WDR6, QARS G 0.42 0.40 1.08E-01 0.85 (0.74 to 0.98) 1.02 (0.85 to 1.22) 0.40 2.05E-01 0.87 (0.76 to 1.01) 1.00 (0.84 to 1.20)
rs6766131 3 49513936 DAG1 Intron C 0.30 0.32 7.66E-02 1.10 (0.96 to 1.26) 1.13 (0.91 to 1.41) 0.34 6.45E-03 1.14 (1.00 to 1.31) 1.28 (1.02 to 1.59)
rs3870336 3 49532861 DAG1 Intron ARIH2, DAG1,
RBM6
A 0.08 0.07 4.75E-01 0.93 (0.77 to 1.12) 0.89 (0.41 to 1.93) 0.08 9.61E-01 1.00 (0.83 to 1.21) 1.03 (0.49 to 2.19)
rs2131109 3 49679991 APEH Intron T 0.46 0.50 3.04E-03 1.05 (0.9 to 1.22) 1.3 (1.11 to 1.53) 0.49 4.44E-02 1.03 (0.88 to 1.20) 1.26 (1.07 to 1.48)
rs11130213 3 49687301 APEH Intron T 0.28 0.32 1.22E-02 1.16 (1.02 to 1.33) 1.12 (0.89 to 1.41) 0.33 5.93E-03 1.11 (0.97 to 1.28) 1.40 (1.11 to 1.76)
rs11130214 3 49710750 MST1 50 WDR6 G 0.31 0.29 3.11E-01 0.90 (0.79 to 1.03) 1.03 (0.82 to 1.3) 0.29 1.86E-01 0.89 (0.78 to 1.02) 0.95 (0.75 to 1.2)
rs241424 6 32912912 PSMB8/
PSMB9
Intron A 0.45 0.46 3.11E-01 1.00 (0.86 to 1.16) 1.14 (0.97 to 1.35) 0.45 9.39E-01 0.94 (0.81 to 1.09) 1.09 (0.92 to 1.29)
rs2071540 6 32920894 PSMB8/
PSMB9
50 T 0.42 0.42 9.42E-01 0.93 (0.81 to 1.07) 1.09 (0.92 to 1.3) 0.41 6.12E-01 0.83 (0.72 to 0.96) 1.18 (0.98 to 1.41)
rs9276831 6 32940011 PSMB8/
PSMB9
Intron G 0.13 0.14 2.05E-01 1.03 (0.89 to 1.20) 1.71 (1.06 to 2.77) 0.15 5.07E-02 1.13 (0.97 to 1.31) 1.59 (0.98 to 2.59)
rs3799858 6 46875647 MEP1A Intron A 0.09 0.09 6.98E-01 0.93 (0.78 to 1.10) 1.66 (0.66 to 4.17) 0.08 1.71E-01 0.84 (0.70 to 1.00) 1.10 (0.39 to 3.08)
rs11174442 12 61041898 USP15 Intron A 0.41 0.41 8.94E-01 1.02 (0.89 to 1.18) 0.99 (0.83 to 1.18) 0.42 5.07E-01 1.05 (0.91 to 1.22) 1.05 (0.88 to 1.26)
rs17765311 15 61577005 USP3 Intron C 0.39 0.35 1.11E-03 0.81 (0.70 to 0.92) 0.91 (0.75 to 1.1) 0.35 1.13E-02 0.93 (0.81 to 1.06) 0.75 (0.61 to 0.91)
rs2649 15 61673646 USP3 Intron T 0.11 0.12 3.02E-01 1.11 (0.95 to 1.30) 1.01 (0.54 to 1.87) 0.11 9.32E-01 0.98 (0.83 to 1.15) 1.09 (0.58 to 2.05)
rs7205423 16 49326763 NOD2/CYLD 50 C 0.45 0.51 1.60E-07 1.23 (1.05 to 1.43) 1.38 (1.17 to 1.62) 0.47 1.99E-01 1.05 (0.90 to 1.21) 1.12 (0.95 to 1.33)
rs12324931 16 49347659 NOD2/CYLD Intron C 0.05 0.10 1.74E-17 2.24 (1.83 to 2.74) 3.03 (1.05 to 8.72) 0.05 2.21E-01 1.22 (0.98 to 1.52) 0.88 (0.23 to 3.34)
rs17314544 16 49377579 NOD2/CYLD Intron T 0.43 0.36 1.42E-08 0.76 (0.66 to 0.88) 0.73 (0.6 to 0.88) 0.41 4.85E-01 0.90 (0.78 to 1.04) 1.03 (0.86 to 1.24)
rs2302759 16 49385102 NOD2/CYLD Intron A 0.18 0.16 4.86E-02 0.88 (0.76 to 1.01) 0.84 (0.58 to 1.21) 0.20 1.80E-01 1.17 (1.01 to 1.35) 0.95 (0.67 to 1.35)
rs9945133 18 28022607 MEP1B 50 G 0.33 0.35 1.10E-01 1.06 (0.92 to 1.21) 1.19 (0.96 to 1.47) 0.33 7.45E-01 0.99 (0.86 to 1.13) 1.13 (0.91 to 1.4)
rs6506963 18 28040950 MEP1B Intron A 0.06 0.07 3.78E-01 1.10 (0.90 to 1.33) 1.16 (0.47 to 2.86) 0.06 8.28E-01 1.08 (0.88 to 1.31) 0.58 (0.2 to 1.71)
rs2302593 19 50888474 QPCTL Intron G 0.49 0.49 6.48E-01 1.16 (1.00 to 1.36) 0.90 (0.77 to 1.06) 0.49 9.50E-01 0.98 (0.84 to 1.14) 1.00 (0.85 to 1.18)
rs11668847 19 50902205 QPCTL Intron G 0.47 0.47 5.50E-01 0.99 (0.86 to 1.16) 0.94 (0.80 to 1.10) 0.49 2.14E-01 1.07 (0.92 to 1.25) 1.09 (0.93 to 1.28)
Bold: significant associations.
*ExonQTL.

























is to degrade unneeded or damaged proteins, but the proteasome
machinery is, as is CYLD, also a key regulator of the NF-κB
pathway.29 30 We tested the effect of the AIEC reference strain
LF82 on the UPS of T84 intestinal epithelial cells by determining
the level of accumulation of poly-ubiquitinated (Ub) proteins,
which is the result of all three major UPS activities (ubiquitinase,
de-ubiquitinase and proteasome activities). T84 cells were
infected with AIEC LF82 bacteria during 3 h. We determined the
Figure 1 Interrelation between CYLD
and adherent-invasive Escherichia coli
(AIEC) LF82 infection. T84 cells were
infected with AIEC LF82 bacteria at a
multiplicity of infection (MOI) of 100,
and CYLD levels in T84 cells were
measured by western blotting with
antiserum against CYLD and β-actin as
an internal control (A). T84 cells were
transfected with CYLD siRNA, total
proteins loaded and immunoblotted
with antibody against CYLD and
β-actin as an internal control (B). T84
transfected cells were infected with
AIEC LF82 at an MOI of 10. The
number of internalised bacteria at 1 h
postinfection (C) and internalised
bacteria at 24 h/1 h postinfection (D)
were determined. T84 cells were
transfected with pEGFP-C1-CYLD
vector, total proteins loaded and
immunoblotted with antibody against
CYLD and β-actin as an internal
control (E). T84 transfected cells were
infected with AIEC LF82 at an MOI of
10. The number of internalised
bacteria at 1 h postinfection (F) and
internalised bacteria at 24 h/1 h
postinfection (G) were determined.
Results are expressed as the
percentage of intracellular bacteria
within transfected T84 cells relative to
untransfected T84 cells, defined as
100%. Data are means±SEM for ≥3
independent experiments. *p<0.05.
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level of accumulation of Ub proteins by using an antibody detect-
ing multi-ubiquitin chains (-K29-, L63- and -K48-linked chains).
Infection of T84 cells with AIEC LF82 bacteria significantly
decreased the level of Ub conjugates by 46% (p<0.001) com-
pared with non-infected cells (figure 2A,B). We also observed
that the decrease in Ub conjugates in AIEC LF82 infected T84
cells is an active bacterial process since this was no longer found
when experiments were performed with heat-killed bacteria
(figure 2C). To further investigate which LF82 bacterial factor
was involved in decreased Ub proteins, we performed experi-
ments with various LF82 mutants affected in their abilities to
interact with T84 cells. We observed that when T84 cells were
infected with mutants LF82-ΔfimH, LF82-ΔfliC, LF82-ΔompA
and LF82-ΔompC, which have decreased ability to adhere and to
invade T84 cells, the decrease in Ub conjugates was not as high
as observed with wild-type LF82 bacteria. In contrast, when T84
cells were infected with LF82-ΔlpfA and LF82-ΔompF mutants,
which are still able to replicate within T84 cells, the level of Ub
proteins in infected cells was not significantly different from that
of LF82 infected cells (figure 2C). Ub proteins are recognised
and degraded by the 26S proteasome, which contains a
chymotrypsin-like proteolytic activity in the β-subunits of its
Figure 2 Regulation of ubiquitin proteasome system and NF-κB pathways by adherent-invasive Escherichia coli (AIEC) LF82 infection on T84 cells.
T84 cells were infected with AIEC LF82 bacteria and isogenic mutants of LF82 deleted for the FimH, lpfA, FliC, OmpA, OmpC, OmpF and the lpf
genes at a multiplicity of infection of 100 or 200. The formation of high molecular weight biotinylated-ubiquitin (Ub) conjugates was determined by
western blotting (A,C) and immune fluorescence staining (B) by using an antibody specifically recognising poly-Ub chains. Representative
immunoblots are shown. Chymotrypsin-like activities of the 26S proteasome (D) were determined by measuring the accumulation of the fluorogenic
cleavage product (amido-4-methylcoumarin). Values were expressed in relative fluorescence unit per microgram of protein per minute. IκB-α protein
level was determined by western blotting with antiserum against IκB-α and β-actin as an internal control (E). Results are expressed as protein
amount relative to β-actin. NF-κB was localised in T84 cells infected with AIEC LF82 bacteria by immune fluorescence staining (F). The accumulation
of Ub conjugates (A,C), chymotrypsin-like activities (C) and IκB-α protein levels (D) are means±SEM for ≥3 independent experiments. *p<0.05
versus uninfected or killed LF82 infected T84 cells, #p<0.05 versus LF82 infected T84 cells.
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proteolytic core complex.31 To see if the decrease in the accumu-
lation of Ub proteins as observed in the presence of AIEC LF82
is in part explained by an effect on 26S proteasome proteolytic
function, we compared the levels of chymotrypsin-like activity in
AIEC LF82 infected T84 cells with non-infected cells. AIEC
LF82 infection induced an MOI-dependent increase in
chymotrypsin-like activity in T84 cells: 1.71-fold (p=0.06)
increase at an MOI of 100, and 2.1-fold (p<0.05) at an MOI of
200 (figure 2D). This suggested that AIEC LF82 bacteria are able
to increase the basal proteolytic level of the 26S proteasome, and
consequently increase its ability to degrade Ub conjugates. In
response to extracellular stimuli, the NF-κB inhibitor IκB-α is
poly-ubiquitinated and degraded by the 26S proteasome, leading
to the activation of NF-κB.32 We tested if, in accordance with the
induction of the 26S proteasome, AIEC LF82 infection favours
IκB-α degradation and subsequently activates the NF-κB
pathway. AIEC LF82 infection induced a significant (p<0.001)
7.7-fold decrease in IκB-α protein level in T84 cells compared
with non-infected cells. This was not observed in the presence of
MG132 (figure 2E). Similarly, we observed a nuclear transloca-
tion of the NF-κB p65 subunit in AIEC LF82-infected T84 cells
(figure 2F).
DISCUSSION
The most strongly associated protease was CYLD, which was
specific for CD. It encodes a cytoplasmic de-ubiquitinating
enzyme and one of its main functions is to protect the host
from an over-reactive inflammatory response by negatively regu-
lating NF-κB.30 Interestingly, a role for CYLD in IBD pathogen-
esis can be suggested as it was identified as one of the most
significantly downregulated genes in the intestine of CD patients
as shown using microarrays.26 In addition, cyld−/− mice dis-
played more severe intestinal inflammation and intestinal
tumourigenesis, compared with wild-type controls.33 it is
important to note the chromosomal location of CYLD adjacent
to NOD2 on 16q12. The (functional) link of NOD2/CARD15
to IBD has been firmly and reproducibly established: there are
several well-characterised polymorphisms in NOD2 leading to
different capacities of the protein products to regulate
NF-κB-mediated inflammatory responses to bacterial compo-
nents in the gut, thus providing a causal explanation for the
observed association with the disease.34 CD GWAS and
meta-analyses have reported strong association on 16q12,3 4
which is attributed to NOD2. Still, Hampe et al found that a
robust association signal in this region remains after stratification
Figure 3 Proposed working model. Several of the genes found to be associated with Crohn’s disease (CD) and/or UC in this study have been
shown to negatively regulate NF-κB: MST1 is a negative regulator of LPS-induced NF-κB activation.43 CYLD can de-ubiquitinate several of the NF-κB
signalling components such as TRAF2/TRAF6 and Nemo (IKK-γ) and toll-like receptors (TLR), particularly TLR2. USP4 de-ubiquitinates TRAF2/TRAF6
in the context of TNF-α- and IL1-β-induced NF-κB activation,44 and targets TAK1 to downregulate TNF-α-induced NF-κB activation.45 APEH is a
negative effector of proteasome activity. While in normal healthy conditions commensal bacteria limit NF-κB signalling through some of these
pathways, in individuals harbouring variant alleles leading to an aberrant expression or altered function of CYLD, USP4, MST1 and/or APEH,
activation of NF-κB is no longer counteracted, resulting in aberrant immune responses and hence inflammation. In addition, CD-associated
pathogenic adherent-invasive Escherichia coli bacteria can modulate ubiquitin proteasome system (UPS) turnover, increase 26S proteasome activities,
IκB-α degradation (directly through the UPS and by negatively regulating CYLD) and subsequently NF-κB activation. The contribution of the UPS in
IBD pathogenesis as revealed in this study could thus be modulated by both genetic and microbial factors.
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by NOD2 polymorphisms.35 In the study reported here, we
show a significant association of CD with CYLD, which appears
to be independent of the association of the three major NOD2
variants. In accordance with our findings, a recent re-analysis of
the WTCCC1 CD data using a multimarker approach also
revealed a significant association of CYLD independent from
NOD2.36 The study by Rivas et al37 where they resequenced
some of the genes identified through GWA studies suggests add-
itional low frequency NOD2 risk alleles. To further disentangle
the independent contribution of CYLD and to find putative
causal (functional) variants within the CYLD gene, the complete
region needs resequencing. In addition, we found a significant
association of USP40, the 3p21 gene region (USP4/APEH/
DAG1/MST1) and USP3 with both CD and UC. It should be
noted however that the observed association results require
further interrogation and conditional analysis of data from a
dense SNP set within these and neighbouring LD blocks before
firm conclusions can be drawn.
Although the genetic studies cannot prove that these genes
are definitely causal (also see online supplementary results), we
do show functional evidence for an important role of CYLD,
and the UPS, in IBD pathogenesis.
Several lines of evidence suggest that one of the hallmarks of
IBD is an alteration in the composition and diversity of the gut
microbiota.6 Pathogenic bacteria like AIEC colonise the ileal
mucosa of CD patients10 and favour a breakdown of the
mucosal barrier, further sustaining the inflammatory response.13
In addition to our genetic results which point towards the impli-
cation of CYLD in IBD pathogenesis, CYLD has been shown to
be downregulated in the intestine of CD patients.26 CYLD, a
key regulator of the NF-κB pathway, can de-ubiquitinate several
of the NF-κB signalling components such as TRAF2/TRAF6 and
Nemo (IKK-γ), which would otherwise lead to the degradation
of IκB-α by the proteasome.30 38 39 In our functional studies,
we show that the pathogenic CD-associated AIEC LF82 bac-
teria, like some other bacteria and viruses,23–25 are able to
modulate CYLD protein levels (hence a way to induce NF-κB
signalling), in turn leading to an increased or a decreased ability
of AIEC LF82 to invade and replicate within intestinal epithelial
cells depending on whether CYLD expression is decreased or
increased respectively. Of note, the levels of AIEC replication
within epithelial cells with decreased CYLD expression were
similar to those seen in epithelial cells with decreased expression
of autophagy-related proteins ATG16L1 or IRGM (immunity-
related GTPase family M protein), for which the encoding genes
are mutated in patients with CD.40 41
CYLD, as well as many of the other genes where we found
evidence for association with IBD (USP40, USP3, USP4, APEH),
is part of the UPS. The main function of the UPS is to degrade
unneeded or damaged proteins, but the proteasome machinery
is, as is CYLD, also a key regulator of the NF-κB pathway. In
the same way as for CYLD, we speculated that AIEC bacteria
could modulate the UPS to induce an inflammatory response.
We show that the pathogenic AIEC LF82 bacteria decrease the
accumulation of poly-ubiquitin conjugates and increase 26S pro-
teasome activity in intestinal epithelial cells, indicating that
AIEC bacteria stimulate ubiquitin-proteasome proteolysis.
Experiments with various LF82 mutants indicated that this
process is dependent on the ability of the bacteria to survive
and/or replicate within host cells. Pivotal to the host inflamma-
tory responses to commensal and pathogenic bacteria is the
NF-κB pathway which is largely regulated by the UPS.42 In
response to extracellular stimuli, the NF-κB inhibitor IκB-α is
poly-ubiquitinated and degraded by the 26S proteasome leading
to NF-κB activation.32 We show that AIEC bacteria induce
proteasome-dependent degradation of IκB-α, leading to a
nuclear translocation of the NF-κB p65 subunit. AIEC bacteria
can thus induce an inflammatory response involving the NF-κB
pathway, which is modulated by the effect of AIEC bacteria on
the 26S proteasome activity.
In summary, we believe that the genetic data together with
the functional data we provide here promote the case for the
candidacy of CYLD as being—at least one—of the causal genes
in the NOD2-CYLD gene region. Our studies identify the UPS
as a major and common (both CD and UC) contributor to IBD
pathogenesis. In the light of the findings of this study, we
propose a working model presented in figure 3 showing that the
major contribution of the UPS in IBD pathogenesis could have
two origins, genetic and/or microbial, both of which being
largely recognised as favouring the development and mainten-
ance of IBD.
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